D.E. Shaw & Co’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

D.E. Shaw & Co’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-193,366	Closed	-$1.93M	–	5348
2022 Q3	$1.93M	Hold	193,366	–	–	﹤0.01%	3044
2022 Q2	$1.91M	Hold	193,366	–	–	﹤0.01%	3115
2022 Q1	$1.9M	Buy	193,366 +82,560	+75%	+$810K	﹤0.01%	3344
2021 Q4	$1.08M	Buy	110,806 +76,407	+222%	+$747K	﹤0.01%	3865
2021 Q3	$337K	Buy	+34,399	New	+$334K	﹤0.01%	4298

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

D.E. Shaw & Co's PKBO Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 193,366 shares — an estimated $1.93M sold.

D.E. Shaw & Co first reported a position in PKBO in Q3 2021 and held it in 5 quarters. The position peaked at $1.93M in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

D.E. Shaw & Co reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
D.E. Shaw & Co sold 193,366 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $1.93M.
D.E. Shaw & Co first reported a position in Peak Bio, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
D.E. Shaw & Co's Peak Bio, Inc. Common Stock position peaked at $1.93M in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.